Chromogranin A Detection in Saliva of Type 2 Diabetes Patients

Martine Soell; Ahmed Feki; Matthias Hannig; Hidehiko Sano; Michel Pinget; Denis Selimović

doi:10.17305/bjbms.2010.2725

Authors

Martine Soell Department of Periodontology, Hautepierre Hospitals, University of Strasbourg INSERM Unit 977
Ahmed Feki Department of Oral Medicine and Oral Surgery, University Hospitals
Matthias Hannig Clinic of Operative Dentistry, Periodontology and Preventive Dentistry, University Hospitals, Saarland University
Hidehiko Sano Department of Restorative Dentistry, Division of Oral Health Science, Hokkaido University Graduate School of Dentistry
Michel Pinget Pôle NUDE, Medicale B, Department of Endocrinology, Diabetes and Metabolic Diseases, University Hospitals
Denis Selimović INSERM Unit 977 Department of Oral Medicine and Oral Surgery, University Hospitals

DOI:

https://doi.org/10.17305/bjbms.2010.2725

Keywords:

Chromogranin A, diabetes type 2, innate immunity saliva

Abstract

Chromogranin A is present in secretion granules of nerve, endocrine and immune cells and is a precursor of several peptides with antibacterial and antifungal properties at micromolar concentrations.

Our aim in this prospective, double blind study, was to determine the expression of chromogranin A and its peptides at protein level in saliva of type 2 diabetic patients and thereby to obtain a new non-invasive diagnostic means for the future.

Saliva was taken from 30 type 2 diabetic patients and 30 healthy individuals at the same time interval in the morning without any oral stimuli. Circadianic periodics in protein productions have been avoided. The presence of chromogranin A and its derived peptides was determined in whole saliva, after centrifugation at 4°C for 12 min at 14 000 rpm, by SDS-PAGE electrophoresis and Immunoblotting (Western Blot). To ensure same protein concentrations Bradford protein quantification assay has been performed before.

For the first time, we have determined an overexpression of chromogranin A in saliva of diabetic patients in 100% of the individuals.

Chromogranin A, a circulating biomarker for epithelial tumours, is also overexpressed in saliva of type 2 diabetic patients. To confirm our results, more studies with a large amount of patients is necessary.